-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Nifeviroc
Category | Human immunodeficiency Virus (HIV) |
CAS | 934740-33-7 |
Description | Nifeviroc is a CCR5 antagonist that can be used to treat HIV type 1 infection. |
Product Information
Synonyms | 4-Nitrobenzyl Allyl(1-(((3S,4R)-1-(Cyclopentanecarbonyl)-4-Hydroxy-4-Phenylpyrrolidin-3-Yl)Methyl)Piperidin-4-Yl)Carbamate |
IUPAC Name | (4-nitrophenyl)methyl N-[1-[[(3S,4R)-1-(cyclopentanecarbonyl)-4-hydroxy-4-phenylpyrrolidin-3-yl]methyl]piperidin-4-yl]-N-prop-2-enylcarbamate |
Molecular Weight | 590.7 |
Molecular Formula | C33H42N4O6 |
Canonical SMILES | C=CCN(C1CCN(CC1)CC2CN(CC2(C3=CC=CC=C3)O)C(=O)C4CCCC4)C(=O)OCC5=CC=C(C=C5)[N+](=O)[O-] |
InChI | InChI=1S/C33H42N4O6/c1-2-18-36(32(39)43-23-25-12-14-30(15-13-25)37(41)42)29-16-19-34(20-17-29)21-28-22-35(31(38)26-8-6-7-9-26)24-33(28,40)27-10-4-3-5-11-27/h2-5,10-15,26,28-29,40H,1,6-9,16-24H2/t28-,33-/m0/s1 |
InChIKey | JNSKQYZFEVKYDB-UVMMSNCQSA-N |
Boiling Point | 761.1±60.0 °C(Predicted) |
Flash Point | 414.1±32.9 °C |
Purity | ≥98% by HPLC |
Density | 1.28±0.1 g/cm3(Predicted) |
Solubility | Soluble in DMSO |
Appearance | Off-white to yellow (Solid) |
Storage | Store at -20°C |
Complexity | 961 |
Exact Mass | 590.31043507 |
Index Of Refraction | 1.631 |
Target | CCR; HIV |
Vapor Pressure | 0.0±2.7 mmHg at 25°C |
XLogP3-AA | 4.4 |